{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T14:29:34Z","timestamp":1784903374106,"version":"3.55.0"},"reference-count":28,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2019,9,11]],"date-time":"2019-09-11T00:00:00Z","timestamp":1568160000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["APMIS"],"published-print":{"date-parts":[[2019,11]]},"abstract":"<jats:p>Since 2012, testing high\u2010risk (HR)HPV has been used as the primary screening test for women \u226535\u00a0years attending the organized cervical cancer screening program in the city of Tampere. We evaluated the contribution of HPV16\/18 genotyping. Data from 2012 and 2013, and the follow\u2010up samples in 2013 and 2014, respectively, were analyzed. Abbott RealTime High\u2010Risk HPV test detecting 14 HRHPV genotypes combined with concurrent genotyping for HPV16 and HPV18 was used. HPV was positive in 794 samples out of 11\u00a0346 HPV tested women (7%). HPV16\/18 was represented in 22% of HPV\u2010positive cases. Negative cervical cytology (NILM) was reported in 51% of HPV\u2010positive samples. HPV16\/18 genotype was accompanied with 50% of HSIL\/ASC\u2010H cases. The predominance of HPV16\/18 in higher grade lesions was even more evident in cervical biopsies as 57% of CIN3 cases were associated with HPV16\/18, and only 20% of carcinomas were associated with nonspecified high\u2010risk (NSHR) genotypes. In agreement with previous studies HPV16\/18 genotypes caused higher grade cytological and histological changes\/pathologies than NSHR genotypes in primary screening. Nevertheless, the majority of HRHPV genotypes detected in the screened population were nonHPV16\/18, and especially within persistent infections, precancerous lesions were found also among women with NSHR genotypes.<\/jats:p>","DOI":"10.1111\/apm.12990","type":"journal-article","created":{"date-parts":[[2019,8,12]],"date-time":"2019-08-12T13:59:33Z","timestamp":1565618373000},"page":"710-716","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["HIGH\u2010RISK HPV testing as the primary screening method in an organized regional screening program for cervical cancer: the value of HPV16 and HPV18 genotyping?"],"prefix":"10.1111","volume":"127","author":[{"given":"Saara","family":"Kares","sequence":"first","affiliation":[{"name":"Department of Pathology Fimlab Laboratories Ltd Tampere Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Veijalainen","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynaecology P\u00e4ij\u00e4t\u2010H\u00e4me Central Hospital Lahti Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivana","family":"Kholov\u00e1","sequence":"additional","affiliation":[{"name":"Department of Pathology Fimlab Laboratories Ltd Tampere Finland"},{"name":"Department of Pathology Faculty of Medicine and Health Technology Tampere University Tampere Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mika","family":"Tirkkonen","sequence":"additional","affiliation":[{"name":"Department of Pathology Fimlab Laboratories Ltd Tampere Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Risto","family":"Vuento","sequence":"additional","affiliation":[{"name":"Department of Microbiology Fimlab Laboratories Ltd Tampere Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heini","family":"Huhtala","sequence":"additional","affiliation":[{"name":"Faculty of Social Sciences Tampere University Tampere Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Tuimala","sequence":"additional","affiliation":[{"name":"Department of Gynaecology and Obstetrics, and Cancer Centre Tampere University Hospital Tampere Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"M\u00e4enp\u00e4\u00e4","sequence":"additional","affiliation":[{"name":"Department of Gynaecology and Obstetrics, and Cancer Centre Tampere University Hospital Tampere Finland"},{"name":"Faculty of Medicine and Health Technology Tampere University Tampere Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Kujala","sequence":"additional","affiliation":[{"name":"Department of Pathology Fimlab Laboratories Ltd Tampere Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,9,11]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)62218-7"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2015.10.147"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.canep.2015.10.021"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.3310\/hta18230"},{"key":"e_1_2_5_6_1","unstructured":"Finnish Cancer Registry Institute for Statistical and Epidemiological Cancer Research. Available from:http:\/\/www.cancersociety.fi\/(Accessed 10\/01\/2019)."},{"issue":"9","key":"e_1_2_5_7_1","first-page":"1","article-title":"Effect of screening for cancer in the Nordic countries on deaths, costs and quality of life up to the year 2017","volume":"36","author":"Hristova L","year":"1997","journal-title":"Acta Oncol"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2011.07.024"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.jncimonographs.a003479"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.26056"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-13-0173"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.1309\/AJCPTUS5EXAS6DKZ"},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/aogs.13013"},{"key":"e_1_2_5_14_1","volume-title":"The Bethesda System for Reporting Cervical Cytology"},{"key":"e_1_2_5_15_1","first-page":"43","article-title":"The Abbott RealTime High Risk HPV test is a clinically validated human papillomavirus assay for triage in the referral population and use in primary cervical cancer screening in women 30\u00a0years and older: a review of validation studies","volume":"22","author":"Poljak M","year":"2013","journal-title":"Acta Dermatovenerol Alp Pannonica Adriat"},{"key":"e_1_2_5_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2015.04.015"},{"key":"e_1_2_5_17_1","unstructured":"Cervical Cancer Screening Current Care Guidelines.Working group set up by the Finnish Medical Society. The Finnish Medical Society Duodecim;2016. Available at:www.kaypahoito.fi"},{"key":"e_1_2_5_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pvr.2015.06.006"},{"key":"e_1_2_5_19_1","doi-asserted-by":"publisher","DOI":"10.1309\/AJCPTGD94EVRSJCG"},{"key":"e_1_2_5_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2013.647"},{"key":"e_1_2_5_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.30090"},{"key":"e_1_2_5_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.29959"},{"key":"e_1_2_5_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(10)70230-8"},{"key":"e_1_2_5_24_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/dji187"},{"key":"e_1_2_5_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.30375"},{"key":"e_1_2_5_26_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0158184"},{"key":"e_1_2_5_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pvr.2016.05.004"},{"key":"e_1_2_5_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)61248-4"},{"key":"e_1_2_5_29_1","unstructured":"European Medicines Agency.Cervarix. Procedural steps taken and scientific information after the authorisation. EMA\/620356\/2012. Available from:http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-Procedural_steps_taken_and_scientific_information_after_authorisation\/human\/000721\/WC500024639.pdf(Accessed 10\/01\/2019)"}],"container-title":["APMIS"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fapm.12990","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/apm.12990","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/apm.12990","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/apm.12990","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T12:52:24Z","timestamp":1694177544000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/apm.12990"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,11]]},"references-count":28,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["10.1111\/apm.12990"],"URL":"https:\/\/doi.org\/10.1111\/apm.12990","archive":["Portico"],"relation":{},"ISSN":["0903-4641","1600-0463"],"issn-type":[{"value":"0903-4641","type":"print"},{"value":"1600-0463","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,11]]},"assertion":[{"value":"2019-03-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-08-05","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-09-11","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}